The complement inhibitors market is projected to grow, driven by the rising prevalence of complement-mediated diseases, intensified R&D efforts, and biotechnological advancements enabling novel ...

Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") announced today that Health Canada has granted a Notice of Compliance (NOC) for Fabhalta® (iptacopan capsules) for the treatment of adult ...

Restricting calorie intake in species such as mice, rhesus monkeys, and fruit flies has been shown to extend their lifespans. In some cases, these animals not only live longer, but are also free of ...

WASHINGTON, 22nd April, 2026 (WAM) -- Researchers have found that slowing ageing may not be linked to dietary restriction as previously believed, but rather to regulating the activity of an immune ...

Yale researchers have previously shown that people who undergo moderate calorie restriction—a 14% reduction in calorie intake ...

AstraZeneca has scrapped an asthma program after the FLAP inhibitor flopped in a phase 2 trial. | AstraZeneca has scrapped an ...

While the Jeep Avenger was initially conceived as a Europe-focused model, its success is now opening doors in other global ...

New targeted therapies are transforming treatment for rare kidney disorders, offering hope of slowing disease progression and ...

Apellis Pharmaceuticals’ long-term GALE study found that Syfovre (pegcetacoplan) delayed geographic atrophy lesion growth by about 1.5 years over five years compared with sham treatment. The therapy, ...

RNA therapies present significant opportunities in targeting a broad range of diseases through various innovative approaches, including antisense oligonucleotides, siRNAs, mRNA vaccines, and aptamers.